ライフサイエンスコーパス: mammalian target of rapamycin

1 ut remained downstream of phosphorylation by mammalian target of rapamycin.

2 major nodes of this pathway: PI3K, AKT, and mammalian target of rapamycin.

3 lanthipeptide cyclases with kinases such as mammalian target of rapamycin.

4 of pharmacological inhibitors of PI3K and/or mammalian target of rapamycin.

5 yrosine kinase associated with inhibition of mammalian target of rapamycin.

6 GSH deficiency compromised the activation of mammalian target of rapamycin-1 (mTOR) and expression of

7 accumulation of TMs correlates with reduced mammalian target of rapamycin activation and the accumul

8 found that C2RD development is dependent on mammalian target of rapamycin activation, T cell-derived

9 aining of resected brain tissue demonstrated mammalian target of rapamycin activation.

10 st, AGS3-deficient macrophages had increased mammalian target of rapamycin activity, reduced transcri

11 ic alterations in Ser/Thr phosphorylation of mammalian target of rapamycin, AKT, extracellular signal

12 REDD1 is an important regulator of Akt and mammalian target of rapamycin and as such plays a key ro

13 on by altering the phosphorylation status of mammalian target of rapamycin and enhanced the bortezomi

14 ermore, Shp2 is a known regulator of the Akt/mammalian target of rapamycin and ERK signaling pathways

15 ubstrates glycogen synthase kinase-3beta and mammalian target of rapamycin and FOXO proteins FOXO1, F

16 for this recruitment is largely dependent on mammalian target of rapamycin and its subsequent inactiv

17 nts, because we observed the reactivation of mammalian target of rapamycin and Notch pathways, driven

18 of rapamycin complex 1-signaling, including mammalian target of rapamycin and raptor, which resulted

19 The interaction between mammalian target of rapamycin and regulatory-associated

20 d inflammation, and modulated changes in the mammalian target of rapamycin and related proteins, sugg

21 nhibition of CB1 Further analyses identified mammalian target of rapamycin as a proinflammatory signa

22 , activates the AMP-activated protein kinase-mammalian target of rapamycin-autophagy pathway, and res

23 ) is a key inhibitor of the protein kinase B/mammalian target of rapamycin axis that regulates growth

24 classical autophagy inducers (starvation or mammalian target of rapamycin blockage) stimulated RACK1

25 l nonrepressed 2 serine/threonine kinase and mammalian target of rapamycin (both molecules involved i

26 he translation of iNOS and COX-2 through the mammalian target of rapamycin complex (mTORC)1.

27 n of PI3K and its downstream targets Akt and mammalian target of rapamycin complex (mTORC1), an effec

28 their polysome association and the status of mammalian target of rapamycin complex 1 (eIF4E-dependent

29 ins, but also signalling molecules, with the mammalian target of rapamycin complex 1 (mTORC1) acting

30 Finally, there was increased mammalian target of rapamycin complex 1 (mTORC1) activat

31 were beta-catenin independent, but required mammalian target of rapamycin complex 1 (mTORC1) activat

32 usly that Trex1-deficient cells have reduced mammalian target of rapamycin complex 1 (mTORC1) activit

33 nt decrease in AMPK activity and increase in mammalian target of rapamycin complex 1 (mTORC1) activit

34 lementary mechanisms including inhibition of mammalian target of rapamycin complex 1 (mTORC1) and act

35 Mammalian target of rapamycin complex 1 (mTORC1) and cel

36 atement of cocaine seeking and inhibited the mammalian target of rapamycin complex 1 (mTORC1) and ext

37 to adiposity and ageing are activated by the mammalian target of rapamycin complex 1 (mTORC1) and p70

38 erial phosphorylation of 4E-BP, primarily by mammalian target of rapamycin complex 1 (mTORC1) at resi

39 The mammalian target of rapamycin complex 1 (mTORC1) control

40 Mammalian target of rapamycin complex 1 (mTORC1) has an

41 uding TFEB is likely due to fisetin-mediated mammalian target of rapamycin complex 1 (mTORC1) inhibit

42 This metabolic imbalance was reversed by mammalian target of rapamycin complex 1 (mTORC1) inhibit

43 The mammalian target of rapamycin complex 1 (mTORC1) inhibit

44 The mammalian target of rapamycin complex 1 (mTORC1) integra

45 Specifically, we show that the mammalian target of rapamycin complex 1 (mTORC1) is a ma

46 Mammalian target of rapamycin complex 1 (mTORC1) is a ma

47 Hyperactive mammalian target of rapamycin complex 1 (mTORC1) is a sh

48 porters, amino acid content, and activity of mammalian target of rapamycin complex 1 (mTORC1) is corr

49 Here, we demonstrated that the mammalian target of rapamycin complex 1 (mTORC1) is requ

50 The mammalian target of rapamycin complex 1 (mTORC1) is the

51 The mammalian target of rapamycin complex 1 (mTORC1) kinase

52 Furthermore, the mammalian target of rapamycin complex 1 (mTORC1) pathway

53 racellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) pathway

54 The hypertrophy-inducing mammalian target of rapamycin complex 1 (mTORC1) pathway

55 s known to function as leucine sensor in the mammalian target of rapamycin complex 1 (mTORC1) pathway

56 OB groups showed greater relative amounts of mammalian target of rapamycin complex 1 (mTORC1) protein

57 The mammalian target of rapamycin complex 1 (mTORC1) regulat

58 s (GTPases), causing release of the inactive mammalian target of rapamycin complex 1 (mTORC1) serine/

59 y the IL-23/phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin complex 1 (mTORC1) signali

60 Metabolic defects included reduced Akt/mammalian target of rapamycin complex 1 (mTORC1) signali

61 Interestingly, mammalian target of rapamycin complex 1 (mTORC1) signali

62 own-regulation of protein kinase B (PKB/Akt)-mammalian target of rapamycin complex 1 (mTORC1) signali

63 tion is thought to trigger downregulation of mammalian target of rapamycin complex 1 (mTORC1) signali

64 ic studies revealed persistent activation of mammalian target of rapamycin complex 1 (mTORC1) signali

65 proteinase-activated receptor 1 (PAR-1) and mammalian target of rapamycin complex 1 (mTORC1) signali

66 Because mammalian target of rapamycin complex 1 (mTORC1) signali

67 ogic or genetic inhibition, respectively, of mammalian target of rapamycin complex 1 (mTORC1) signali

68 By blocking mechanistic/mammalian target of rapamycin complex 1 (mTORC1) signall

69 strate that the nutrient-sensing mechanistic/mammalian target of rapamycin complex 1 (mTORC1) stimula

70 Activation of the mammalian target of rapamycin complex 1 (mTORC1) subunit

71 Inhibition of PKA, PI3K, Akt, and mammalian target of rapamycin complex 1 (mTORC1) suppres

72 family GTPase, which binds to and activates mammalian target of rapamycin complex 1 (mTORC1) when GT

73 This event requires the mammalian target of rapamycin complex 1 (mTORC1), a sign

74 The mammalian target of rapamycin complex 1 (mTORC1), a tran

75 vated Galphai3 and enhanced downstream Akt2, mammalian target of rapamycin complex 1 (mTORC1), and ma

76 of influencing signal transduction, via the mammalian target of rapamycin complex 1 (mTORC1), and re

77 3beta (GSK3beta) activity, activation of the mammalian target of rapamycin complex 1 (mTORC1), and su

78 S-1), phosphatidyl inositol-3 kinase (PI3K), Mammalian target of rapamycin complex 1 (mTORC1), nuclea

79 Its canonical target, mammalian target of rapamycin complex 1 (mTORC1), plays

80 leads to inhibition of signaling through the mammalian Target of Rapamycin Complex 1 (mTORC1), reduct

81 When Raptor, a critical scaffold protein for mammalian target of rapamycin complex 1 (mTORC1), was ac

82 pared the effects of fructose and glucose on mammalian target of rapamycin complex 1 (mTORC1), which

83 rotein for Rheb and negatively regulates the mammalian target of rapamycin complex 1 (mTORC1).

84 le organs are characterised by activation of mammalian target of rapamycin complex 1 (mTORC1).

85 uced activation of nuclear factor-kappaB and mammalian target of rapamycin complex 1 (mTORC1).

86 Constitutive activation of the mammalian target of rapamycin complex 1 and S6 kinase (m

87 Activation of mammalian target of rapamycin complex 1 by Akt resulted

88 keletal muscle myostatin expression, reduced mammalian target of rapamycin complex 1 function, and hy

89 e cytokine combinations robustly upregulated mammalian Target of Rapamycin Complex 1 in human NK cell

90 -induced metabolic changes were sensitive to mammalian Target of Rapamycin Complex 1 inhibition by ra

91 TFEB translocation after starvation-induced mammalian target of rapamycin complex 1 inhibition, Park

92 Towards Rags 1, a negative regulator of the mammalian target of rapamycin complex 1 signaling pathwa

93 epilepsy, and an aberrant activation of the mammalian target of rapamycin complex 1 signaling pathwa

94 Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor b

95 at ketamine enhanced this effect through the mammalian target of rapamycin complex 1 synaptogenic pat

96 We found that Akt-mTORC1 (mammalian target of rapamycin complex 1) signaling was i

97 ha-ketoglutarate-dependent inhibition of the mammalian target of rapamycin complex 1, and deficiency

98 or stress stimulation in a process involving mammalian target of rapamycin complex 1, and this intera

99 conditions increased the phosphorylation of mammalian target of rapamycin complex 1, ribosomal prote

100 100 directly repressed several components of mammalian target of rapamycin complex 1-signaling, inclu

101 cogen synthase kinase-3beta was dependent on mammalian target of rapamycin complex 1.

102 atenin, whereas hypertrophy was dependent on mammalian target of rapamycin complex 1.

103 e II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1.

104 GPCR-promoted activation of Akt signaling by mammalian target of rapamycin complex 2 (mTORC2) and the

105 that loss of Pdcd4 increases the activity of mammalian target of rapamycin complex 2 (mTORC2) and the

106 Our prior work identified the mammalian target of rapamycin complex 2 (mTORC2) as a ke

107 Further investigation shows that mammalian target of rapamycin complex 2 (mTORC2) contrib

108 central hub of the metabolism machinery, the mammalian target of rapamycin complex 2 (mTORC2) has bee

109 acts through phospholipase D2 (PLD2) and the mammalian target of rapamycin complex 2 (mTORC2) to limi

110 This process invokes activation primarily of mammalian target of rapamycin complex 2 (mTORC2), which

111 In contrast, insulin, but not LPS, induced mammalian target of rapamycin complex 2 (mTORC2)-depende

112 in, which is the most important component of mammalian target of rapamycin complex 2 (mTORC2).

113 Signaling analyses suggest the mammalian target of rapamycin complex 2 (mTORC2)/Akt sig

114 1 by TGF-beta involves activation of MEK and mammalian target of rapamycin complex 2 pathways.

115 sequently triggers activation of the MEK and mammalian target of rapamycin complex 2, which cooperate

116 P9 expression and that both are required for mammalian target of rapamycin complex-1 and S6K1 activat

117 target of rapamycin complex 1 (mTORC1), and mammalian target of rapamycin complex-2 (mTORC2) signali

118 tein translation owing to diminished mTORC1 (mammalian target of rapamycin complex1) activity in ER-s

119 either by starvation or by inhibition of the mammalian target of rapamycin, enhanced lysosomal cleara

120 thogenic T cell subsets through CB1-mediated mammalian target of rapamycin inhibition in human kerati

121 The impact of mammalian target of rapamycin inhibition on posttranspla

122 nals, CTLA-4 blockade and rapamycin-mediated mammalian target of rapamycin inhibition, during in vivo

123 tly upregulated in response to starvation or mammalian target of rapamycin inhibition, suggesting tha

124 isk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-expo

125 order to investigate the hypothesis that the mammalian target of rapamycin inhibitor everolimus (EVR)

126 The mammalian target of rapamycin inhibitor everolimus may b

127 Early conversion to mammalian target of rapamycin inhibitor monotherapy has

128 n of alternative adjunctive therapies (eg, a mammalian target of rapamycin inhibitor or belatacept) m

129 reversion of CGD inflammatory status by the mammalian target of rapamycin inhibitor rapamycin on the

130 ry impairment was prevented by the selective mammalian target of rapamycin inhibitor temsirolimus and

131 Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been propos

132 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppr

133 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppr

134 te to SCC development, whereas conversion to mammalian target of rapamycin inhibitors (mTOR-i) could

135 Conversion to mammalian target of rapamycin inhibitors (mTORi) is ofte

136 Immunosuppressive therapy with mammalian target of rapamycin inhibitors (mTORi) require

137 pressives, calcineurin inhibitors (CNi), and mammalian target of rapamycin inhibitors (mTORi), may no

138 De novo use of mammalian target of rapamycin inhibitors after kidney tr

139 proteasome inhibitors (eg, carfilzomib), and mammalian target of rapamycin inhibitors are promising a

140 Newer mammalian target of rapamycin inhibitors can significant

141 Over the past decade, mammalian target of rapamycin inhibitors have received c

142 tions with phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitors in breast cance

143 Mammalian target of rapamycin inhibitors may confer card

144 Mammalian target of rapamycin inhibitors, but not CNi, r

145 ve drugs, such as calcineurin inhibitors and mammalian target of rapamycin inhibitors.

146 some inhibitors, immunomodulatory drugs, and mammalian target of rapamycin inhibitors.

147 mTOR, the mammalian target of rapamycin, integrates growth factor

148 These results provide evidence that mammalian target of rapamycin is a key player involved i

149 the potency of CC-115, a novel inhibitor of mammalian target of rapamycin kinase (TORK) and DNA-depe

150 s markedly attenuated by inhibitors of PI3K, mammalian target of rapamycin, MAPKs (p38, ERK, and JNK)

151 n mice with intestine-specific disruption of mammalian target of rapamycin (Mtor) (mTOR(f/f):Villin-c

152 dly after inactivation of the protein kinase mammalian target of rapamycin (mTOR) (or mechanistic tar

153 nventional DCs, rapamycin effectively blocks mammalian target of rapamycin (mTOR) 1 signaling induced

154 PKCzeta inhibits insulin resistance-mediated mammalian target of rapamycin (mTOR) activation and cycl

155 Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) activation was inve

156 ized by inefficient autophagy as a result of mammalian target of rapamycin (mTOR) activation, AMPKalp

157 ndocytosis resulted in a failure to maintain mammalian target of rapamycin (mTOR) activity and to sta

158 Furthermore, IL-10 suppresses mammalian target of rapamycin (mTOR) activity through th

159 ion required sustained TCR stimulation, late mammalian target of rapamycin (mTOR) activity, and HIF-1

160 ut chronic signaling differed markedly, with mammalian target of rapamycin (MTOR) and extracellular s

161 or treatment was unable to phosphorylate the mammalian target of rapamycin (mTOR) and stimulate GluA1

162 We identified c-Jun kinase and mammalian target of rapamycin (mTOR) as components of tw

163 Mammalian target of rapamycin (mTOR) complex 2 (mTORC2)

164 kinase Akt via its direct phosphorylation by mammalian target of rapamycin (mTOR) complex 2 (mTORC2)

165 Inhibition of mammalian target of rapamycin (mTOR) complex-1 (mTORC1)

166 Mammalian target of rapamycin (mTOR) complexes, mTORC1 a

167 I3Ks) and their downstream mediators AKT and mammalian target of rapamycin (mTOR) constitute the core

168 Aberrant signaling by the mammalian target of rapamycin (mTOR) contributes to the

169 n of fatty acid biosynthesis was found to be mammalian target of rapamycin (mTOR) dependent, as it wa

170 Mammalian target of rapamycin (mTOR) enhances translatio

171 To assess safety and efficacy of mammalian target of rapamycin (mTOR) inhibition in combi

172 pare the effects of metformin and the direct mammalian target of rapamycin (mTOR) inhibitor rapamycin

173 Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been

174 g the onset of puberty in children receiving mammalian target of rapamycin (mTOR) inhibitors are limi

175 The role of mammalian target of rapamycin (mTOR) inhibitors in de no

176 The mammalian target of rapamycin (mTOR) inhibitors sirolimu

177 stimulation and resistances to SMI (such as mammalian target of rapamycin (mTOR) inhibitors).

178 The mammalian target of rapamycin (mTOR) inhibitors, sirolim

179 Mammalian target of rapamycin (mTOR) integrates multiple

180 Mammalian target of rapamycin (mTOR) is a central kinase

181 Mammalian target of rapamycin (mTOR) is a conserved seri

182 The mammalian target of rapamycin (mTOR) is a crucial signal

183 Mammalian target of rapamycin (mTOR) is a key protein ki

184 Mammalian target of rapamycin (mTOR) is a serine/threoni

185 Although the mammalian target of rapamycin (mTOR) is an essential reg

186 The mammalian target of rapamycin (mTOR) is commonly activat

187 The mammalian target of rapamycin (mTOR) is essential for Th

188 Activation of the mechanistic/mammalian target of rapamycin (mTOR) kinase in models of

189 Expression of the mammalian target of rapamycin (mTOR) kinase target 4E-BP

190 f mTORC2, or pharmacologic inhibition of the mammalian target of rapamycin (mTOR) kinase, promotes gl

191 y T-cell proliferation assays; the effect of mammalian target of rapamycin (mTOR) manipulation in MSC

192 Targeting mammalian target of rapamycin (mTOR) may overcome endocr

193 These results suggest that inhibitors of the mammalian target of rapamycin (mTOR) might be beneficial

194 Inhibition of mammalian target of rapamycin (mTOR) or activation of tr

195 hagy, lactate dehydrogenase (LDH) assay, and mammalian target of rapamycin (mTOR) pathway activation

196 phate-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway are found i

197 Conversely, BPA exposure down-regulated the mammalian target of rapamycin (mTOR) pathway by phosphor

198 lation of eIF4E-binding protein 1 (4ebp1), a mammalian target of rapamycin (mTOR) pathway component t

199 g that Rab8a is a novel regulator of the Akt/mammalian target of rapamycin (mTOR) pathway downstream

200 The mammalian target of rapamycin (mTOR) pathway is a known

201 The mammalian target of rapamycin (mTOR) pathway is an impor

202 ulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predomin

203 Kim-1 expression led to activation of the mammalian target of rapamycin (mTOR) pathway, and inhibi

204 lity of inflammatory cells by activating the mammalian target of rapamycin (mTOR) pathway.

205 corresponded with reduced activation of the mammalian target of rapamycin (mTOR) pathway.

206 least in part, through overactivation of the mammalian target of rapamycin (mTOR) pathway.

207 sing its phosphorylation by S6K1 through the mammalian target of rapamycin (mTOR) pathway.

208 Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway.

209 ys revealed that both cellular autophagy and mammalian target of rapamycin (mTOR) pathways were activ

210 ationship between peg-IFN-alpha and the DAPK-mammalian target of rapamycin (mTOR) pathways.

211 Dysregulated mammalian target of rapamycin (mTOR) promotes cancer, bu

212 dy, we investigated whether mutations in the mammalian target of rapamycin (mTOR) regulators, NPRL2 a

213 The mammalian target of rapamycin (mTOR) senses and incorpor

214 kdown of ILK prevented periostin-induced Akt/mammalian target of rapamycin (mTOR) signaling and ADPKD

215 of action has been elusive, though enhanced mammalian target of rapamycin (mTOR) signaling is a majo

216 n of microglia-SV40 causes activation of the mammalian target of rapamycin (mTOR) signaling kinase, a

217 factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway a

218 Subsequently, the activated mammalian target of rapamycin (mTOR) signaling pathway a

219 The mammalian target of rapamycin (mTOR) signaling pathway h

220 targets of miR-15b/16, we observed that the mammalian target of rapamycin (mTOR) signaling pathway w

221 Inhibiting the mammalian target of rapamycin (mTOR) signaling pathway w

222 TBCK has been shown to regulate the mammalian target of rapamycin (mTOR) signaling pathway,

223 -Kit regulates VEGF-A expression via the Akt/mammalian target of rapamycin (mTOR) signaling pathway.

224 e signaling, synaptic transmission, eIF2 and mammalian target of rapamycin (mTOR) signaling potential

225 d with uric acid priming, with NF-kappaB and mammalian target of rapamycin (mTOR) signaling strongly

226 Further, the mammalian target of rapamycin (mTOR) signaling was impli

227 of phosphatidyl inositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling, driving

228 -isoxazolepropionic acid (AMPA) receptor and mammalian target of rapamycin (mTOR) signaling, respecti

229 linked this anomalous autophagy to defective mammalian target of rapamycin (mTOR) signaling, which af

230 IL-15 augmented mammalian target of rapamycin (mTOR) signaling, which co

231 p53 suppresses carcinogenesis by inhibiting mammalian target of rapamycin (mTOR) signaling.

232 n response to nutrient supply is mediated by mammalian target of rapamycin (mTOR) signaling.

233 Inhibition of the mammalian target of rapamycin (mTOR) suppressed the DNMT

234 (ROCK1 and ROCK2), p70 S6 kinase (S6K), and mammalian target of rapamycin (mTOR) were increased in P

235 egulated kinase (ERK)-dependent signaling of mammalian target of rapamycin (mTOR), a key protein synt

236 The mammalian target of rapamycin (mTOR), a kinase that regu

237 Mammalian target of rapamycin (mTOR), a regulator of gro

238 tinct from eIF3 complexes containing S6K1 or mammalian target of rapamycin (mTOR), and appears to rep

239 ce exercise (RE) activates signalling by the mammalian target of rapamycin (mTOR), and it has been su

240 in (Rapa), a small molecule inhibitor of the mammalian target of rapamycin (mTOR), exhibits a strikin

241 tor receptor-associated factor 6 (TRAF6) and mammalian target of rapamycin (mTOR), respectively.

242 the cell-growth-promoting pathway involving mammalian target of rapamycin (mTOR), RGC axons regenera

243 , Gln, and finally, a checkpoint mediated by mammalian target of rapamycin (mTOR), which integrates s

244 rotein (Yap) were required for activation of mammalian target of rapamycin (mTOR)-Akt, accumulation o

245 We found that AAV induced mammalian target of rapamycin (mTOR)-dependent autophagy

246 opionic acid (AMPA) receptors, which trigger mammalian target of rapamycin (mTOR)-dependent structura

247 Mammalian target of rapamycin (mTOR)-directed eukaryotic

248 of the autophagy-lysosome pathway (ALP) in a mammalian target of rapamycin (mTOR)-independent approac

249 Mammalian target of rapamycin (mTOR)-inhibitors have ant

250 ed sensitivity to the inhibitors of PI3K and mammalian target of rapamycin (mTOR).

251 amycin, implicating a partial involvement of mammalian target of rapamycin (mTOR).

252 ed with activation of AMPK and inhibition of mammalian target of rapamycin (mTOR).

253 maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR).

254 degradation by activating the protein kinase mammalian target of rapamycin (mTOR).

255 quire de novo protein synthesis regulated by mammalian target of rapamycin (mTOR).

256 activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).

257 inhibit heat shock protein 90 (Hsp90) and/or mammalian target of rapamycin (mTOR).

258 er docetaxel chemoresistance mediated by the mammalian target of rapamycin (mTOR)/sphingosine-kinase-

259 LRRK2 acts to influence macroautophagy, the mammalian target of rapamycin (mTOR)/Unc-51-like kinase

260 sensing (LYNUS) apparatus that controls the mammalian target of rapamycin (mTORC1) kinase complex at

261 il and collagen III deposition and decreased mammalian target of rapamycin (mTORC1/2) expression ex v

262 active mechanistic target of rapamycin (aka mammalian target of rapamycin) (mTORC1), a master metabo

263 f ribosome biogenesis, and (2) the impact of mammalian target of rapamycin on ribosome biogenesis, an

264 hagy and phosphorylation of protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase (A

265 The mammalian target of rapamycin pathway is a central cellu

266 Our findings suggest that modulation of the mammalian target of rapamycin pathway may hold promise f

267 cts occurred without altered activity of the mammalian target of rapamycin pathway nor did they invol

268 s in macrophages limited the activity of the mammalian target of rapamycin pathway, a sensor of cellu

269 target the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway, and insulin-like

270 )-triphosphate, which transactivates the Akt/mammalian target of rapamycin pathway, leading to activa

271 fects of negative regulators of the PI3K-Akt-mammalian target of rapamycin pathway, phosphatase and t

272 n to be involved in glioma signaling and the mammalian target of rapamycin pathway.

273 rgy in FGFR3-mutant cell lines between mTOR (mammalian target of rapamycin) pathway inhibitors and ch

274 y inhibition of the AKT and complex 1 of the mammalian target of rapamycin pathways and activation of

275 iral oncogene homolog 1 and complex 1 of the mammalian target of rapamycin pathways and stimulated th

276 in the mitogen-activated protein kinase and mammalian target of rapamycin pathways and the inverse c

277 -AMPK and lower levels of phosphorylation of mammalian target of rapamycin (phospho-mTOR).

278 sphorylated protein kinase B, phosphorylated mammalian target of rapamycin, phosphorylated eukaryotic

279 tidylinositol-4,5-bisphosphate 3-kinase/Akt/ mammalian target of rapamycin (PI3K/Akt/mTOR) pathway ha

280 osphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway ho

281 unds targeting phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling are

282 both the MAPK and phosphoinositide-3 kinase/mammalian target of rapamycin (PI3K/mTOR) signaling path

283 a antioxidant activity and regulation of the mammalian target of rapamycin protein kinase (mTOR).

284 ay is an upstream regulator of the oncogenic mammalian target of rapamycin/ribosomal protein S6 kinas

285 o assemble CaMKIV with key components of the mammalian target of rapamycin/ribosomal protein S6 kinas

286 and identify an important novel modulator of mammalian target of rapamycin signaling and autophagy in

287 phatase activity in the nucleus can regulate mammalian target of rapamycin signaling and neuronal gro

288 Mechanistically, TLR7 induced PI3K/mammalian target of rapamycin signaling in CMP, which wa

289 rowth by altering both energy production and mammalian target of rapamycin signaling in human liver c

290 early radial glia and enriched activation of mammalian target of rapamycin signaling in outer radial

291 and inhibition of acetyl-CoA carboxylase and mammalian target of rapamycin signaling pathways, leadin

292 Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell

293 thways, including cell cycle, apoptosis, Akt/mammalian target of rapamycin signaling, metastasis and

294 fects of rapamycin, a selective inhibitor of mammalian target of rapamycin signaling, on HO formation

295 alterations in the proteins associated with mammalian target of rapamycin signalling were detected i

296 threonine kinase and increased expression of mammalian target of rapamycin, suggesting reduced amino

297 tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additio

298 pamycin and regulatory-associated protein of mammalian target of rapamycin was unaltered in response

299 emarkably, rFlaA:Betv1 induced activation of mammalian target of rapamycin, which increased the metab

300 ed autophagic flux led to co-localization of mammalian target of rapamycin with LC3-positive autophag

301 Furthermore, pharmacological inhibition of mammalian target of rapamycin with Torin1 also was not s